Global Experts Establish New Name for PCOS to Reflect Multisystem Disease – CU Anschutz newsroom

Global health experts have officially renamed polycystic ovary syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS). The decision follows a landmark global consensus study published on May 12, 2026, in The Lancet, aiming to better reflect the complex, multisystem nature of the condition.

The renaming marks a shift in medical understanding, moving away from the view that the condition is primarily a gynecological disorder. Instead, PMOS is recognized as a multisystem condition that impacts endocrine, metabolic, reproductive, dermatological, and psychological health.

This change is intended to address the inaccuracies associated with the previous name. For decades, the term polycystic ovary syndrome was considered limiting because many patients diagnosed with the condition do not actually have ovarian cysts.

Addressing Diagnostic Gaps and Patient Care

The mischaracterization of the condition as primarily ovarian has had tangible consequences for the more than 170 million people worldwide who are affected. According to the consensus study, the narrow definition has contributed to delayed diagnoses and fragmented care.

the previous terminology created stigma and resulted in missed opportunities for early intervention regarding cardiovascular and metabolic risks. By redefining the condition as a polyendocrine and metabolic syndrome, medical professionals can better identify and treat the broader health implications.

Melanie Cree, MD, PhD, a pediatric endocrinologist at the University of Colorado Anschutz and one of two U.S.-based pediatric endocrinologists involved in the international effort, emphasized that the change is about more than terminology.

Renaming this condition is more than semantics; it’s about finally recognizing the full reality of what patients experience

Melanie Cree, MD, PhD

Dr. Cree further noted that for too long, the narrow definition of PCOS has overlooked its metabolic and hormonal complexity, leaving many patients undiagnosed or misunderstood.

Global Implementation and Clinical Updates

The transition to the name Polyendocrine Metabolic Ovarian Syndrome is expected to be integrated across several medical frameworks to ensure consistent adoption worldwide. This implementation will include updates to:

• International disease classification systems
• Clinical guidelines for diagnosis and treatment
• Medical education curricula

By updating these systems, health experts aim to usher in a new era of awareness that recognizes the interplay between hormonal imbalances and metabolic health, potentially leading to more comprehensive and personalized care for patients.